Compounding Drug Development Drug Pricing 
STAT
DECEMBER 4, 2024
Also, compounding pharmacies fire back at Novo Nordisk for its assertion that GLP-1 drugs are too difficult to compound. Lots today on GLP-1s: First we see tirzepatide outperforming semaglutide in a head-to-head study in obesity. Also, a Michael Gilman company pivots and more. Read the rest…
STAT
APRIL 29, 2025
Good morning, we’ve got a bunch of news this morning about GLP-1 drugs, compounding, and biotechs’ interactions with the FDA. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Let’s get into it.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
MARCH 7, 2025
Today, we unpack Marty Makary’s Senate confirmation hearing, see a new ruling against GLP-1 compounders, examine the effects of the NIH patent freeze, and explore the tumultuous biotech job market. Sign up to get our biotech newsletter in your inbox. Read the rest…
STAT
JUNE 20, 2024
We have adjusted our settings to accept postcards and telegrams… After taking legal action last year, Eli Lilly filed even more lawsuits against several spas, compounders and wellness centers over unapproved versions of tirzepatide, which is the active ingredient in Mounjaro and Zepbound, STAT notes.
Drug Patent Watch
DECEMBER 18, 2024
According to a 2021 study by the Tufts Center for the Study of Drug Development, the average cost to develop a new drug is a staggering $2.6 A robust patent strategy often involves filing multiple applications at different stages of drug development. billion[1].
European Pharmaceutical Review
JUNE 24, 2022
The review was impacted by Brexit and the COVID-19 pandemic, which compounded existing issues surrounding high drug pricing and patient access that had been brewing since 2016 and highlighted several shortcomings in the EU’s pharmaceutical system. This obviously presents a huge magnitude of risk for drug developers,” he noted.
pharmaphorum
JUNE 2, 2022
While in 2021, orphan drugs made up over half of all the US FDA’s approvals, with the figures in European being similarly high – 19 out of 54 approved new active substances. The report estimates that the orphan drug market will grow twice as fast as the non-orphan market, with a 2021 to 2026 compound annual growth rate of 12%.
Expert insights. Personalized for you.
265 
Let's personalize your content